Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
AU · Author affiliation · country only
Oxidation Biology Laboratory Florey Institute for Neuroscience and Mental Health Parkville Victoria AustraliaLocation evidence
Melbourne, AU · Author affiliation
Department of Pathology University of Melbourne Parkville Victoria AustraliaLocation evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Ceruloplasmin is an iron‐export ferroxidase that is abundant in plasma and also expressed in glia. We found a ∼80% loss of ceruloplasmin ferroxidase activity in the substantia nigra of idiopathic Parkinson disease (PD) cases, which could contribute to the pro‐oxidant iron accumulation that characterizes the pathology. Consistent with a role for ceruloplasmin in PD etiopathogenesis, ceruloplasmin knockout mice developed parkinsonism that was rescued by iron chelation. Additionally, peripheral infusion of ceruloplasmin attenuated neurodegeneration and nigral iron elevation in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model for PD. These findings show, in principle, that intravenous ceruloplasmin may have therapeutic potential in PD. Ann Neurol 2013;73:554–559